US FDA warns Sanofi-Aventis over misleading Uroxatral promotion
This article was originally published in Scrip
Executive Summary
The US FDA has warned Sanofi-Aventis that a promotional item known as a tent card for its alpha(1)-blocker Uroxatral (alfuzosin extended-release tablets) is misleading because the front side presents effectiveness claims but omits "any risk information associated with its use". Indication and risk information only appear on the back of the card.